CTLA4 and cancer: Currently, with an unprecedented sustained and stable antitumor response, immunotherapy cytotoxic T lymphocyte-associated antigen 4 (CTLA4) or programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) has demonstrated remarkable efficacy against various types of cancer (6).